Literature DB >> 8113385

Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes.

S Kamchonwongpaisan1, G Chandra-ngam, M A Avery, Y Yuthavong.   

Abstract

Plasmodium falciparum infecting hemoglobin (Hb)H and/or Hb Constant Spring erythrocytes has higher resistance to artemisinin in vitro than when infecting normal erythrocytes. This is due to low drug accumulation of infected erythrocytes resulting from competition with uninfected variant erythrocytes, which have a higher accumulation capacity than genetically normal cells. Drug accumulation of the parasite was shown to be saturable and dependent on metabolic energy. The 50% inhibitory concentrations (IC50's) for the parasite in HbH/Hb Constant Spring erythrocytes were decreased when normal erythrocytes were added to the infected cells, and correspondingly, the IC50's in normal erythrocytes were increased when HbH/Hb Constant Spring erythrocytes were added to the infected cells. The changes of IC50 corresponded to the variation in drug accumulation of mixtures of normal and variant erythrocytes of different compositions. The IC50's for the parasite in variant erythrocytes were also greatly decreased when the hematocrit of the culture was lowered, while the IC50's in normal erythrocytes were independent of the hematocrit. The increase in IC50 values for the parasites infecting variant erythrocytes was also related to the decrease in parasite accumulation, indicating that drug accumulation capacity of the parasite also has a role in determining drug sensitivity. Artemisinin sensitivity therefore is determined by its accessibility to the parasite, which is decreased in infected variant erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113385      PMCID: PMC293858          DOI: 10.1172/JCI116994

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Decreased sensitivity of artesunate and chloroquine of Plasmodium falciparum infecting hemoglobin H and/or hemoglobin constant spring erythrocytes.

Authors:  Y Yuthavong; P Butthep; A Bunyaratvej; S Fucharoen
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

Review 2.  Common genetic disorders of the red cell and the 'malaria hypothesis'.

Authors:  D J Weatherall
Journal:  Ann Trop Med Parasitol       Date:  1987-10

3.  Role of haemichromes in the formation of inclusion bodies in haemoglobin H disease.

Authors:  E A Rachmilewitz; J Peisach; T B Bradley; W E Blumberg
Journal:  Nature       Date:  1969-04-19       Impact factor: 49.962

4.  A rapid method for concentrating schizont-infected red cells of Plasmodium falciparum.

Authors:  P Dejkriengkraikhul; R Santiyanont; P Wilairat
Journal:  Southeast Asian J Trop Med Public Health       Date:  1982-12       Impact factor: 0.267

5.  Uptake of [3H] dihydroartemisinine by erythrocytes infected with Plasmodium falciparum in vitro.

Authors:  H M Gu; D C Warhurst; W Peters
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

6.  Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria.

Authors:  I A Clark; N H Hunt
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

7.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

8.  The development and spread of drug-resistant malaria.

Authors:  W H Wernsdorfer
Journal:  Parasitol Today       Date:  1991-11

Review 9.  Qinghaosu (artemisinin): an antimalarial drug from China.

Authors:  D L Klayman
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

10.  Qinghaosu-mediated oxidation in normal and abnormal erythrocytes.

Authors:  M D Scott; S R Meshnick; R A Williams; D T Chiu; H C Pan; B H Lubin; F A Kuypers
Journal:  J Lab Clin Med       Date:  1989-10
View more
  11 in total

1.  Reaction of artemisinin with haemoglobin: implications for antimalarial activity.

Authors:  Rangiah Kannan; Krishan Kumar; Dinkar Sahal; Shrikant Kukreti; Virander S Chauhan
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum.

Authors:  S Kaewpongsri; K Sriprawat; R Suwanarusk; D E Kyle; U Lek-Uthai; M Leimanis; K M Lwin; A P Phyo; J Zwang; B Russell; F Nosten; L Renia
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate.

Authors:  W Ittarat; S Looareesuwan; P Pootrakul; P Sumpunsirikul; P Vattanavibool; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Artemisone uptake in Plasmodium falciparum-infected erythrocytes.

Authors:  Sophie Pooley; Farrah A Fatih; Sanjeev Krishna; Michael Gerisch; Richard K Haynes; Ho-Ning Wong; Henry M Staines
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 5.  Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy.

Authors:  S R Meshnick; T E Taylor; S Kamchonwongpaisan
Journal:  Microbiol Rev       Date:  1996-06

6.  Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.

Authors:  Sri Riyati Sugiarto; Brioni R Moore; Julie Makani; Timothy M E Davis
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

7.  Artemisinin effectiveness in erythrocytes is reduced by heme and heme-containing proteins.

Authors:  Napawan Ponmee; Tatsanee Chuchue; Prapon Wilairat; Yongyuth Yuthavong; Sumalee Kamchonwongpaisan
Journal:  Biochem Pharmacol       Date:  2007-03-15       Impact factor: 5.858

8.  Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 9.  Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.

Authors:  Mark A Travassos; Miriam K Laufer
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

10.  Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali.

Authors:  Abdoulaye K Kone; Issaka Sagara; Mahamadou A Thera; Alassane Dicko; Aldiouma Guindo; Seidina Diakite; Joseph Kurantsin-Mills; Abdoulaye Djimde; Asikiya Walcourt; Ogabara Doumbo
Journal:  Malar J       Date:  2010-11-21       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.